TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27608768

Group type: EXPERIMENTAL
Intervention: Video-assisted remote consultations at a regional medical centre (RMC)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standard consultation in the orthopaedic outpatient clinic at the University Hospital of North Norway (UNN)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Video-assisted consultations
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Ancillary analyses
Number of subjects: 400
Study: 25142039

Group type: EXPERIMENTAL
Intervention: Memantine (5 to 20 mg/day; n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 40
Study: 23283817

Group type: EXPERIMENTAL
Intervention: GIST patients (n=15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 45
Study: 20334585

Group type: EXPERIMENTAL
Intervention: Vitex agnus castus (VAC, BNO 1095)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 18684057

Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (Ontak®)
Number of subjects: 0
Study: 16567324

Group type: COMPARATOR
Intervention: Placebo responders
Number of subjects: 904
Study: 12760700

Group type: EXPERIMENTAL
Intervention: Surface-penetrating sealant (Protect‐it!‐PI)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: One bottle adhesive system (Single Bond‐SB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-sealed control
Number of subjects: 30
Study: 10757577

Group type: EXPERIMENTAL
Intervention: Prilocaine (80 mg, 20 mg/ml)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lidocaine (80 mg, 20 mg/ml)
Number of subjects: 100
Study: 1591947

Group type: EXPERIMENTAL
Intervention: Allopurinol (50 mg orally 4 times a day)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Dimethyl sulphoxide (DMSO, 500 mg orally 4 times a day)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 198
Study: 2413292

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 28

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 28
Study: 30715378

Group type: EXPERIMENTAL
Intervention: Pharmacological and non-pharmacological interventions for CIPN
Number of subjects: 0
Study: 29331384

Group type: EXPERIMENTAL
Intervention: Different feedback delivery methods (specific methods not detailed)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Positive feedback
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Negative feedback
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Feedback accuracy (specific accuracy levels not detailed)
Number of subjects: 500
Study: 26414317

Group type: EXPERIMENTAL
Intervention: Postexercise regional circulatory occlusion (RCO) for 2-min recovery
Number of subjects: 11

Group type: COMPARATOR
Intervention: Normal recovery (NR)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: RCO + CO2
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control trial (NR)
Number of subjects: 11
Study: 25455006

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 33557

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 33557

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 33557
Study: 23506685

Group type: EXPERIMENTAL
Intervention: Oscillating red, green and blue light exposure
Number of subjects: 20
Study: 20979471

Group type: EXPERIMENTAL
Intervention: Tiotropium bromide
Number of subjects: 210
Study: 18071721

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study: 15721217

Group type: EXPERIMENTAL
Intervention: Left rTMS
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Right rTMS
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 39
Study: 14512398

Group type: EXPERIMENTAL
Intervention: Tailored fluorouracil, epirubicin, and cyclophosphamide (FEC) therapy for nine courses
Number of subjects: 525

Group type: COMPARATOR
Intervention: Induction FEC therapy for three courses followed by high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin (CTCb)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Both treatments (FEC and CTCb)
Number of subjects: 525
Study: 11249802

Group type: EXPERIMENTAL
Intervention: Gabapentin (900 to 3,600 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study: 9032851

Group type: EXPERIMENTAL
Intervention: Gamma Knife radiosurgery
Number of subjects: 50
Study: 1888819

Group type: EXPERIMENTAL
Intervention: 200 mg cimetidine suspension four times daily
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 3514018

Group type: EXPERIMENTAL
Intervention: Fenfluramine; utilized for 10 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo; during the placebo period
Number of subjects: 10
Study: 28951431

Group type: EXPERIMENTAL
Intervention: Physical Exercise (PE)
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behavioural Therapy (ICBT)
Number of subjects: 821

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Self-rated work ability
Number of subjects: 821
Study: 26394646

Group type: EXPERIMENTAL
Intervention: Simvastatin (S)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Simvastatin + Ezetimibe (S+E)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (placebo run-in period)
Number of subjects: 39
Study: 24753128

Group type: EXPERIMENTAL
Intervention: Randomization
Number of subjects: 1176
Study: 22866941

Group type: EXPERIMENTAL
Intervention: TV Commercial Stepping
Number of subjects: 58

Group type: COMPARATOR
Intervention: Walking 30 min/day
Number of subjects: 58
Study: 19931380

Group type: EXPERIMENTAL
Intervention: Inactivated, subvirion vaccine containing 15microg of influenza A/H5N1 hemagglutinin (HA) by the intramuscular (IM) route
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Inactivated, subvirion vaccine containing 45microg of influenza A/H5N1 hemagglutinin (HA) by the intramuscular (IM) route
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Inactivated, subvirion vaccine containing 3microg of H5 HA by the intradermal (ID) route
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Inactivated, subvirion vaccine containing 9microg of H5 HA by the intradermal (ID) route
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Inactivated, subvirion vaccine containing 45microg of H5 HA by the intramuscular (IM) route
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Inactivated, subvirion vaccine containing 15microg of H5 HA by the intramuscular (IM) route
Number of subjects: 100
Study: 22863058

Group type: EXPERIMENTAL
Intervention: 4 g colestyramine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 12 g colestyramine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Both doses of colestyramine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (water alone)
Number of subjects: 9
Study: 16450921

Group type: EXPERIMENTAL
Intervention: Visual feedback provided during the FAAF test
Number of subjects: 32

Group type: COMPARATOR
Intervention: No visual feedback provided during the FAAF test
Number of subjects: 32
Study: 12615670

Group type: EXPERIMENTAL
Intervention: rosiglitazone (8 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 9854438

Group type: EXPERIMENTAL
Intervention: Reinforcement for choosing the word in each pair that contained a double letter.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Encouragement to test irrelevant hypotheses.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sitting in an uncomfortable chair.
Number of subjects: 0
Study: 9121751

Group type: EXPERIMENTAL
Intervention: Excimer laser photorefractive keratectomy (PRK)
Number of subjects: 107
Study: 2483004

Group type: EXPERIMENTAL
Intervention: Neoadjuvant PVB therapy
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Neoadjuvant CAP therapy
Number of subjects: 56
Study: 55648

Group type: EXPERIMENTAL
Intervention: Levamisole (1-25 mg/kg twice daily for two consecutive days every week)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Levamisole (greater than 2-5 mg/kg/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 30983001

Group type: EXPERIMENTAL
Intervention: 0.1% triamcinolone acetonide cream with wet wraps
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 0.1% triamcinolone acetonide ointment with wet wraps
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Patient preference for ointment
Number of subjects: 39
Study: 28684191

Group type: EXPERIMENTAL
Intervention: Sodium nitrate (15 mmol)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 25324159

Group type: EXPERIMENTAL
Intervention: Early Childhood Oral Health Impact Scale (ECOHIS)
Number of subjects: 286
Study: 23350579

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (10 mL of Evicel)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 24
Study: 21722228

Group type: EXPERIMENTAL
Intervention: Acetaminophen (500-1000 mg) + Ibuprofen (100-400 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibuprofen (100-400 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetaminophen (500-1000 mg)
Number of subjects: 0
Study: 18457747

Group type: EXPERIMENTAL
Intervention: Educational intervention using SMS and Internet for 6 months
Number of subjects: 34
Study: 16517327

Group type: EXPERIMENTAL
Intervention: Ulinastatin (300000 IU intravenously before XU)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no additional treatment)
Number of subjects: 16
Study: 12968959

Group type: EXPERIMENTAL
Intervention: Preservation of the intercostobrachial (ICB) nerve
Number of subjects: 85

Group type: COMPARATOR
Intervention: Nerve section
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 85
Study: 10620007

Group type: EXPERIMENTAL
Intervention: Nutritional supplements and dietary counselling
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no supplements or specific nutritional advice)
Number of subjects: 15
Study: 9020549

Group type: EXPERIMENTAL
Intervention: Newborns with premature ablation of placenta
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy newborns
Number of subjects: 20
Study: 1585291

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice a day for 10 days
Number of subjects: 82

Group type: COMPARATOR
Intervention: Erythromycin 500 mg six hourly for 10 days
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 82

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 82
Study: 4032549

Group type: EXPERIMENTAL
Intervention: 3 gm. ampicillin intramuscularly in divided doses 1 hour before, at the time of, and 6 hours after catheter insertion (Group 1)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 1 gm. ampicillin intramuscularly every 8 hours (Group 2)
Number of subjects: 78

Group type: COMPARATOR
Intervention: No antimicrobial prophylaxis (Group 3)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Group 3 (Control)
Number of subjects: 78
Study: 28936572

Group type: EXPERIMENTAL
Intervention: Hot spring balneotherapy for 5 months
Number of subjects: 362

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 362
Study: 27137122

Group type: EXPERIMENTAL
Intervention: Whole-body vibration and electromyostimulation (WBV+ES)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 17
Study: 24662223

Group type: EXPERIMENTAL
Intervention: Loaded vibration (LV) training group (n = 7)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Unloaded vibration (ULV) training group (n = 7)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Loaded training (LT) group (n = 7)
Number of subjects: 21
Study: 21956438

Group type: EXPERIMENTAL
Intervention: Intravenously administered 6% v/v ethanol to a target blood alcohol concentration of 0.08%
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intravenously administered 6% v/v ethanol
Number of subjects: 2
Study: 20158918

Group type: EXPERIMENTAL
Intervention: $AUD5 payment per chlamydia test
Number of subjects: 12

Group type: COMPARATOR
Intervention: No payment for testing
Number of subjects: 12
Study: 18672535

Group type: COMPARATOR
Intervention: Ethinyl estradiol (EE) and norethindrone (NE) alone
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol (EE) and norethindrone (NE) with darunavir/ritonavir (DRV/r)
Number of subjects: 19
Study: 15904555

Group type: EXPERIMENTAL
Intervention: Educational booklet
Number of subjects: 332

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 332
Study: 12322847

Group type: EXPERIMENTAL
Intervention: Loratadine plus Pseudoephedrine Sulfate Repetabs Tables (LTD+PSE Repetabs) (Loratadine 5 mg + Pseudoephedrine 120 mg) twice daily
Number of subjects: 56

Group type: COMPARATOR
Intervention: loratadine (5 mg) twice daily and pseudoephedrine (60 mg) quarter daily
Number of subjects: 56
Study: 9925128

Group type: EXPERIMENTAL
Intervention: 750 mL black currant and apple juice
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 1000 mL black currant and apple juice
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 1500 mL black currant and apple juice
Number of subjects: 5
Study: 7589375

Group type: EXPERIMENTAL
Intervention: Terbutaline and budesonide turbohalers used twice daily over 12 weeks
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Psychological assessment using HADS, IIP, and semi-structured interview
Number of subjects: 102
Study: 2156387

Group type: EXPERIMENTAL
Intervention: Live attenuated rotavirus vaccine (derived from rhesus rotavirus strain MMU 18006 and human serotype 1 strain Wa)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Live attenuated rotavirus vaccine
Number of subjects: 26
Study: 7208539

Group type: EXPERIMENTAL
Intervention: Cefuroxime short-term prophylaxis (1 day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ampicillin plus oxacillin long-term prophylaxis (5 days)
Number of subjects: 44
Study: 30887824

Group type: EXPERIMENTAL
Intervention: Behavioral activation (BA) with sexual risk reduction (SRR) counseling
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control condition (two sessions of SRR)
Number of subjects: 41
Study: 28395659

Group type: EXPERIMENTAL
Intervention: Abelmoschus manihot (huangkui capsule, 2.5 g, three times per day)
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Losartan potassium (100 mg/d)
Number of subjects: 1600
Study: 26802783

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg) + deferred laser (N = 111)
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg) + prompt laser (N = 124)
Number of subjects: 828

Group type: COMPARATOR
Intervention: Laser/very deferred ranibizumab (N = 198)
Number of subjects: 828

Group type: COMPARATOR
Intervention: Triamcinolone (4 mg) + laser/very deferred ranibizumab (N = 125)
Number of subjects: 828
Study: 24979561

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ketamine
Number of subjects: 80
Study: 22249272

Group type: EXPERIMENTAL
Intervention: Gemcitabine and S-1 (GS)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Gemcitabine alone (G)
Number of subjects: 117
Study: 20538021

Group type: EXPERIMENTAL
Intervention: Chronic pain patients
Number of subjects: 19

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 19
Study: 18187961

Group type: EXPERIMENTAL
Intervention: E-CMF (adjuvant anthracycline-based dose-dense sequential chemotherapy)
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: E-T-CMF (adjuvant anthracycline-based dose-dense sequential chemotherapy)
Number of subjects: 595
Study: 15819813

Group type: EXPERIMENTAL
Intervention: Pancreas-kidney transplantation (PTx)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group of nontransplanted type 1 diabetic patients
Number of subjects: 48
Study: 12390062

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (≤325 mg/d)
Number of subjects: 6300
Study: 9090581

Group type: EXPERIMENTAL
Intervention: Triggered images (with respiratory triggering)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Triggered images with echo train length of 8 and flow compensation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nontriggered images
Number of subjects: 10
Study: 7947873

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 0
Study: 3606936

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 12
Study: 29438131

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 74
Study: 27682300

Group type: EXPERIMENTAL
Intervention: Direct cortical fixation using spiked washer screw (group I)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Post-tie using washer screw (group II)
Number of subjects: 80
Study: 25051491

Group type: EXPERIMENTAL
Intervention: Xpert MTB/Rif test on pleural fluid
Number of subjects: 116

Group type: COMPARATOR
Intervention: Pleural tissue culture and/or histopathology (reference standard)
Number of subjects: 116
Study: 22623392

Group type: COMPARATOR
Intervention: MUFA diet (20% daily energy MUFA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MED diet (21% daily energy MUFA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SFA diet (19% daily energy as SFA)
Number of subjects: 0
Study: 19793143

Group type: EXPERIMENTAL
Intervention: Electroanatomic mapping (EAM) and ablation of MRAT with linear ablation at the mid‐diastolic isthmus (MDI).
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Electroanatomic mapping (EAM) and ablation of MRAT.
Number of subjects: 52
Study: 19198574

Group type: EXPERIMENTAL
Intervention: Daily interferon alpha‐2b (4 MIU s.c. for patients > 65 kg or 0.06 MIU/kg < 65 kg) + ribavirin
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: PEG‐interferon alpha‐2b (100 microg s.c. weekly for patients > 65 kg or 1.5 microg/kg weekly for patients < 65 kg) + ribavirin
Number of subjects: 336

Group type: COMPARATOR
Intervention: Interferon alpha‐2b (3 MIU s.c. TIW) + ribavirin
Number of subjects: 336
Study: 16370079

Group type: EXPERIMENTAL
Intervention: Olanzapine (Zyprexa) 7.5 mg
Number of subjects: 1493

Group type: EXPERIMENTAL
Intervention: Quetiapine (Seroquel) 200 mg
Number of subjects: 1493

Group type: EXPERIMENTAL
Intervention: Risperidone (Risperdal) 1.5 mg
Number of subjects: 1493

Group type: EXPERIMENTAL
Intervention: Ziprasidone (Geodon) 40 mg
Number of subjects: 1493

Group type: EXPERIMENTAL
Intervention: Perphenazine (Trilafon) 8 mg
Number of subjects: 1493
Study: 15156097

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine high dose (12 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine low dose (4 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (both doses)
Number of subjects: 18
Study: 11122312

Group type: EXPERIMENTAL
Intervention: ILM airway insertion/intubation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ILM removal at 1 min
Number of subjects: 120

Group type: COMPARATOR
Intervention: ILM removal at 3 min
Number of subjects: 120

Group type: COMPARATOR
Intervention: ILM removal at 5 min
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Multiple intubation attempts
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ILM insertion/intubation and removal
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Timing of ILM removal
Number of subjects: 120
Study: 9251961

Group type: EXPERIMENTAL
Intervention: Verbal arithmetic task presented first
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonverbal arithmetic task
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Verbal arithmetic task presented second
Number of subjects: 20
Study: 8337193

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment programme in a group setting with components of relaxation, cognitive restructuring, and promotion of well-being
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment programme
Number of subjects: 0
Study: 3709586

Group type: EXPERIMENTAL
Intervention: Epidural morphine injection (group A)
Number of subjects: 98

Group type: COMPARATOR
Intervention: No epidural morphine (group B)
Number of subjects: 98
Study: 3169499

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (starting dosage, 2.5 mg/kg.day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vehicle placebo
Number of subjects: 12
Study: 31552428

Group type: EXPERIMENTAL
Intervention: Sleep intervention (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (n = 50)
Number of subjects: 100
Study: 31284074

Group type: EXPERIMENTAL
Intervention: Low-dose colchicine (0.5 mg daily)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study: 27613939

Group type: EXPERIMENTAL
Intervention: 6mg nicotine gum
Number of subjects: 94

Group type: COMPARATOR
Intervention: 4mg nicotine lozenge
Number of subjects: 94

Group type: COMPARATOR
Intervention: 4mg lozenge
Number of subjects: 94

Group type: COMPARATOR
Intervention: 4mg gum
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 2mg nicotine gum
Number of subjects: 94

Group type: COMPARATOR
Intervention: 4mg nicotine gum
Number of subjects: 94
Study: 26003545

Group type: EXPERIMENTAL
Intervention: Low tidal volume strategy (4 to 6 ml/kg PBW)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High tidal volume strategy (8 to 10 ml/kg PBW)
Number of subjects: 0
Study: 23174860

Group type: EXPERIMENTAL
Intervention: α(1)-blockade (prazosin, 1 mg/20 kg body wt)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 21636583

Group type: EXPERIMENTAL
Intervention: PI‐free combination including efavirenz
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: PI‐free combination including nevirapine
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: PI‐free combination including abacavir
Number of subjects: 439

Group type: COMPARATOR
Intervention: First‐line boosted PI‐containing cART regimen (non-switch)
Number of subjects: 439
Study: 19490035

Group type: EXPERIMENTAL
Intervention: Pregabalin 150-600 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day fixed-dosage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0